Skip to main content

Table 1 Demographic and Clinical characteristics of STEMI patients grouped by SYNTAX score

From: Prognostic value of the SYNTAX score on myocardial injury and salvage in STEMI patients after primary percutaneous coronary intervention: a single-center retrospective observational study

Characteristics

Whole (n = 149)

SS ≤ 22 (n = 96)

SS > 22 (n = 53)

p-value

Age (years)

59.89 ± 10.86

58.32 ± 11.47

62.72 ± 9.09

0.011

Male

108 (72.5)

68 (70.8)

40 (75.5)

0.572

BMI (kg/m2)

25.78 ± 3.42

26.25 ± 3.62

24.92 ± 2.86

0.023

Hypertension

64 (43.0)

45 (46.9)

19 (35.8)

0.228

Smoking

91 (61.1)

56 (58.3)

35 (66.0)

0.385

Hyperlipidemia

17 (11.4)

11 (11.5)

6 (11.3)

1.0

Diabetes

35 (23.5)

21 (21.9)

14 (26.4)

0.550

Initial heart rate

76.79 ± 13.35

76.53 ± 11.69

77.27 ± 16.07

0.645

GRACE score

109.97 ± 22.73

107.32 ± 22.81

114.75 ± 22.06

0.089

CRUSADE score

18.0 (9.0,24.0)

15.0 (9.0,22.0)

18.5 (12.8,29.3)

0.056

Procedural data for the patients

Time of pain to door

    

  ≤ 6 h

99 (66.4)

60 (62.5)

39 (73.6)

0.206

  > 6 h

50 (33.6)

36 (37.5)

14 (26.4)

Time of door to reperfusion/angiography only (h)

1.17 (0.68,80.91)

1.23 (0.69,10.10)

0.98 (0.63,234.73)

0.830

Time of pain to reperfusion/ angiography only (h)

7.05 (4.44,95.91)

7.33 (4.68,23.39)

6.22 (4.27,246.73)

0.629

Culprit lesion

    

 LAD

60 (40.3)

37 (38.5)

23 (43.4)

0.603

 Non-LAD

89 (59.7)

59 (61.5)

30 (56.6)

No. of diseased vessels

    

 0

4 (2.7)

4 (4.2)

0 (0)

 < 0.001

 1

54 (36.2)

51 (53.1)

3 (5.7)

 2

45 (30.2)

29 (30.2)

16 (30.2)

 3

46 (30.9)

12 (12.5)

34 (64.2)

Initial TIMI flow grade

    

 0–1

93 (62.4)

52 (54.2)

41 (77.4)

0.008

 2–3

56 (37.6)

44 (45.8)

12 (22.6)

Initial TIMI thrombus grade

    

 0–3

56 (37.6)

45 (46.9)

11 (20.8)

0.002

 4–5

93 (62.4)

51 (53.1)

42 (79.2)

Final TIMI flow grade

    

 0/1

9 (6.0)

5 (5.2)

4 (7.5)

0.721

 2/3

140 (94.0)

91 (94.8)

49 (92.5)

Post-dilatation in patients with stent implanting

    

 Yes

86 (81.9)

57 (81.4)

29 (82.9)

0.858

 No

19 (18.1)

13 (18.6)

6 (17.1)

Mode of reperfusion (n, %)

    

 Balloon angioplasty

29 (19.5)

17 (17.7)

12 (22.6)

0.675

 PCI with stent

105 (70.5)

70 (72.9)

35 (66.0)

 Angiography only

15 (10.1)

9 (9.4)

6 (11.3)

Laboratory data

    

 Creatinine clearance rate ( mL/min)

102.24 (77.99,123.64)

111.12 (79.81,127.97)

92.11 (72.60,108.06)

0.016

 cTnI (ng/ml)

0.32 (0.03,4.08)

0.35 (0.06,5.81)

0.18 (0.03,2.27)

0.207

 WBC (109/L)

10.51 ± 3.62

10.64 ± 3.69

10.27 ± 3.53

0.566

 AST (U/L)

29.35 (19.03,61.88)

31.70 (19.85,67.0)

26.80 (18.60,55.20)

0.378

 CK (U/L)

176.0 (108.5,579.0)

218.0 (110.75,616.0)

158.0 (96.0,558.25)

0.337

 CKMB (U/L)

25.55 (16.13,75.90)

25.85 (16.33,61.68)

24.5 (16.0,83.90)

0.821

 LDL ( mmol/L)

2.96 ± 0.85

2.89 ± 0.76

3.07 ± 0.99

0.272

 APOA (g/L)

1.06 ± 0.22

1.06 ± 0.22

1.05 ± 0.21

0.704

 APOB (g/L)

0.99 ± 0.26

0.96 ± 0.22

1.06 ± 0.30

0.038

Medication

    

 Aspirin

146 (98.0%)

93 (96.9)

53 (100.0)

0.553

 Clopidogrel

46 (30.9)

33 (34.4)

13 (24.5)

0.358

 Ticagrelor

101(67.8)

62(64.6)

39(73.6)

 No clopidogrel or ticagrelor

2(1.3)

1(1.0)

1(1.9)

 Statin

143(96.0)

92(95.8)

51(96.2)

1.0

 Beta blocker

86(57.7)

56(58.3)

30(56.6)

0.864

 ACEI

6(4.0)

3(3.1)

3(5.7)

0.666

 ARB

29(19.5)

17(17.7)

12(22.6)

0.519

  1. Categorical data are presented as absolute (percentage), normally distributed data as mean ± standard deviation, and other continuous data with medians including first and third quartiles in brackets
  2. BMI body weight index; GRACE the Global Registry of Acute Coronary Events; CRUSADE Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines; LAD left anterior descending artery; TIMI thrombolysis in myocardial infarction; WBC white blood cell; LDL low-density lipoprotein; ACEI Angiotensin-Converting Enzyme Inhibitors; ARB Angiotensin Receptor Blocker